State of Wyoming Raises Stock Holdings in CareDx, Inc. $CDNA

State of Wyoming boosted its holdings in CareDx, Inc. (NASDAQ:CDNA) by 185.2% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,537 shares of the company’s stock after buying an additional 15,284 shares during the quarter. State of Wyoming’s holdings in CareDx were worth $409,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in CDNA. Price T Rowe Associates Inc. MD grew its stake in shares of CareDx by 1.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,218 shares of the company’s stock worth $739,000 after acquiring an additional 711 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of CareDx by 4.8% during the second quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock valued at $542,000 after purchasing an additional 1,280 shares during the last quarter. Quarry LP bought a new position in CareDx during the fourth quarter valued at approximately $25,000. Allspring Global Investments Holdings LLC lifted its position in CareDx by 9.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 19,091 shares of the company’s stock valued at $365,000 after purchasing an additional 1,675 shares during the period. Finally, SG Americas Securities LLC lifted its position in CareDx by 8.3% during the first quarter. SG Americas Securities LLC now owns 29,949 shares of the company’s stock valued at $520,000 after purchasing an additional 2,292 shares during the period.

Insider Buying and Selling at CareDx

In related news, CEO John Walter Hanna, Jr. sold 39,900 shares of CareDx stock in a transaction on Monday, June 29th. The stock was sold at an average price of $29.24, for a total transaction of $1,166,676.00. Following the transaction, the chief executive officer directly owned 661,959 shares in the company, valued at approximately $19,355,681.16. The trade was a 5.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Hannah Valantine sold 12,103 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $23.11, for a total value of $279,700.33. Following the sale, the director directly owned 36,686 shares of the company’s stock, valued at $847,813.46. This represents a 24.81% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 78,936 shares of company stock valued at $2,093,708 over the last 90 days. 2.40% of the stock is currently owned by company insiders.

CareDx Stock Performance

Shares of NASDAQ CDNA opened at $37.14 on Monday. CareDx, Inc. has a 12-month low of $11.26 and a 12-month high of $40.47. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -232.12 and a beta of 2.43. The firm has a 50 day moving average of $26.91 and a 200 day moving average of $21.94.

CareDx (NASDAQ:CDNA) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.23. The business had revenue of $117.70 million for the quarter, compared to the consensus estimate of $102.03 million. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. The company’s quarterly revenue was up 39.3% on a year-over-year basis. During the same period last year, the firm earned $0.09 earnings per share. Sell-side analysts predict that CareDx, Inc. will post 0.22 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on CDNA shares. BTIG Research lifted their target price on shares of CareDx from $28.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Weiss Ratings cut CareDx from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, July 15th. William Blair upgraded CareDx to a “hold” rating in a research note on Thursday, July 16th. Wall Street Zen raised CareDx from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 3rd. Finally, Craig Hallum reiterated a “hold” rating and set a $35.00 price objective on shares of CareDx in a research report on Thursday, July 16th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $33.67.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non?invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post?transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor?derived cell?free DNA assay used primarily in kidney transplant monitoring.